Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Holding GPCR?
Track your performance easily
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.61 - $75.02
Previous Close$38.99
Volume704.26K
Average Volume (3M)692.37K
Market Cap
$2.08B
Enterprise Value$1.15B
Total Cash (Recent Filing)$927.12M
Total Debt (Recent Filing)$4.67M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Nov 12, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding57,196,520
10 Day Avg. Volume681,477
30 Day Avg. Volume692,374
Standard Deviation0.26
R-Squared0.24
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-10.92
Forecast
1Y Price Target
$88.14Price Target Upside122.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Structure Therapeutics, Inc. Sponsored ADR News
PremiumCompany Announcements
Structure Therapeutics Announces Key Executive Leadership Changes
PremiumCompany Announcements
Structure Therapeutics Appoints Angus Russell to Board
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsGSBR-1290 demonstrated a 4% weight loss in Japanese participants at a 60 mg dose after just four weeks, aligning with Phase 2a data and indicating a strong efficacy profile.
Drug Development And Market PotentialOral GLP-1's like GSBR-1290 are poised to drive significant market growth in obesity treatments, potentially expanding the market to over $100 billion.
Strategic Positioning And M&A SpeculationPending positive data, GSBR-1290 positions GPCR as a potential target for mergers and acquisitions, supported by its best-in-class potential and broad pipeline.
Bears Say
Clinical PerformanceDanuglipron's tolerability issues are significant, with worse performance compared to competitors like LLY’s orforglipron.
Market SentimentGPCR shares are down ~9% and off ~39% since GPCR’s Phase 2 diabetic data, which is considered overdone.
Product CompetitionNovo's delay in defining the clinical program for its subcutaneous amycretin creates uncertainty about its competitiveness against GPCR.
---
Ownership Overview
15.35% Insiders
35.76% Mutual Funds
0.10% Other Institutional Investors
47.69% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $26.61 and its highest was $75.02 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 12, 2024 which is in 25 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 08, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.04.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.19.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,196,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went down -2.088%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 101M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.14 (122.46% Upside)
$88.14 (122.46% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 554.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.96%
12-Months-Change
Fundamentals
Return on Equity
-17.71%
Trailing 12-Months
Asset Growth
312.80%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$88.14
▲(122.46% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+20.60%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +20.60% per trade.
---